Literature DB >> 2409414

Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

E G Sandstrom, J C Kaplan, R E Byington, M S Hirsch.   

Abstract

Phosphonoformate, an inhibitor of reverse transcriptase in a number of retroviruses, was shown to have a dose-related inhibitory effect on human T-cell lymphotropic virus type III (HTLV-III) replication in the H9 cell line in vitro. HTLV-III replication was eliminated at a concentration of 680 mumol, a non-cytotoxic dose. A lower dose of 132 mumol inhibited HTLV-III replication by more than 98%, as measured by reverse transcriptase activity, compared with untreated infected cultures. Reverse transcriptase activity in HTLV-III particles was completely inhibited by 5.0 mumol phosphonoformate.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Clinical Research; Diseases; Drugs--therapeutic use; Hiv Infections; In Vitro; Research Methodology; Treatment; Viral Diseases

Mesh:

Substances:

Year:  1985        PMID: 2409414     DOI: 10.1016/s0140-6736(85)92255-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  64 in total

Review 1.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Authors:  A M Taburet; C Katlama; C Blanshard; G Zorza; D Gazzard; E Dohin; B G Gazzard; C Frostegard; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

4.  Treatment of CMV retinitis in an AIDS patient.

Authors:  J F Acheson; S M Shah; D J Spalton; C Bradbeer; R N Thin
Journal:  Br J Ophthalmol       Date:  1987-11       Impact factor: 4.638

Review 5.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 6.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

7.  Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.

Authors:  X B Kong; Q Y Zhu; R M Ruprecht; K A Watanabe; J M Zeidler; J W Gold; B Polsky; D Armstrong; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G Tachedjian; M French; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation.

Authors:  R W Buckheit; J Germany-Decker; K Qualls-Goodwin; B J Bowdon; W M Shannon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.